Posted by Michael Wonder on 22 Jul 2017
EMA’s CHMP issues positive opinion for avelumab for the treatment of metastatic Merkel cell carcinoma
21 July 2017 - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU.
Merck and Pfizer today announced that the CHMP of the EMA has recommended the approval of avelumab (Bavencio) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma, a rare and aggressive skin cancer.
The European Commission will now review the CHMP’s recommendation, with a decision expected in the third quarter of 2017.
